About Vivo Capital
Vivo Capital is a private equity firm founded in 1996. It is primarily based in Palo Alto, United States. As of Sep 2026, Vivo Capital is an active investor with a portfolio of 227 companies, comprising 227 funding rounds and 5 acquisitions. In the last 12 months, it has participated in 15 funding rounds and has made 1 acquisition. The firm primarily invests in companies based in United States and China. Its portfolio is spread across a wide range of sectors from Life Sciences to High Tech. Its latest investment was a $***** Post IPO round in Korsana on Sep 10, 2026 which also saw participation from Off Track Betting Parlor, Venrock and other investors.
A lot of funds co-invest with Vivo Capital, with names like RA Capital Management sharing a substantial percentage of its portfolio.
Vivo Capital has a team of 68 people, including 14 partners.
Key Metrics
Founded Year
1996
Location
Palo Alto, United States
Portfolio Companies
Portfolio Sectors
Portfolio Locations
Acquisition Deals
Investment Deals
Vivo Capital's Portfolio
Vivo Capital has a portfolio of 227 companies. They have invested in a total of 227 companies. Their most recent investment was in Korsana (Post IPO round) on Sep 10, 2026. Here are the most recent investments by Vivo Capital:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Sep 10, 2026 | Post IPO | 6653 | ||
Aug 05, 2026 | Series B | 6012 | ||
Jul 24, 2026 | Series D | 5146 | ||
Jun 08, 2026 | Series B | 7967 |
Vivo Capital has acquired 5 companies. Their most recent acquisition was of Dominique Dutscher on Feb 03, 2026. Here are the most recent acquisitions by Vivo Capital:
Acquisition Date | Company | Short Description | Total Funding | Founded Year |
|---|---|---|---|---|
Feb 03, 2026 | Supplier of equipment and consumables for biotechnology research laboratories | - | 1982 | |
Jan 08, 2021 | Provider of drug development, manufacturing and regulatory services | - | 2016 | |
Jun 26, 2017 | Developer of vaccines against multiple infectious diseases | - | 2001 | |
Feb 01, 2021 | Developer of surgical knives and wound closure products | - | 1999 |
Here is the portfolio snapshot of Vivo Capital:
Investments by Year
The maximum number of investments were made in 2021
Acquisitions by Year
The maximum number of acquisitions were made in 2017
Portfolio by Location
Companies are primarily in United States and China
Portfolio by Sector
Companies are primarily in Life Sciences
Team profile of Vivo Capital
Vivo Capital has a team of 68 members including 14 Partners, 3 Venture Partners and 16 Principals located in United States, China and 3 more locations. Vivo Capital's team sits on the board of 1 company.Here is a list of top team members in Vivo Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Palo Alto | - | - | |
Partner | Chaoyang | - | - | |
Partner | Singapore | - | - | |
Partner | Palo Alto | - | - | |
Partner | Palo Alto | - | - | |
Partner | Taipei | - | - | |
Partner | Palo Alto | - | - | |
Partner | Palo Alto | - | - | |
Partner | - | - | - | |
Partner | Huangpu | - | - | |
Partner | San Francisco | - | - |
Co-investors of Vivo Capital
Over the past 30 years, 326 investors have co-invested in Vivo Capital's portfolio companies.
- Top Co-investors of Vivo Capital: 326 investors entered a company along with Vivo Capital. These include investors like RA Capital Management (29 companies).
Vivo Capital News
•
SonoThera raises $125M for non-viral gene therapy approachEndpoints•Jun 10, 2026•SonoThera, Medical Excellence Capital, UCB Ventures, Leaps by Bayer and 10 others
•
Full-Life Technologies Secures $150 Million Financing for Clinical Development and ManufacturingPR Newswire•May 19, 2026•Full-Life Technologies, TSG Capital, HSG, Junson Capital and 7 others
•
OriCell Raises $40M More as It Looks to Go PublicEndpoints•Apr 10, 2026•OriCell Therapeutics, Vivo Capital, Qiming Venture Partners
•
Syneron Bio Closes $150M Series B FinancingFinSMEs•Apr 03, 2026•LAV, Global League, True Light Capital, 5Y Capital and 10 others
•
AN2 Therapeutics Announces $40 Million Private Placement FinancingFinancial Times•Mar 09, 2026•Commodore Capital, AN2 Therapeutics, Vivo Capital
•
LBO France sells Dutscher Group to Vivo CapitalPrivate Equity Wire•Feb 03, 2026•Vivo Capital, LBO France
•
EQT Life Sciences Backs Kinaset Therapeutics' USD103 Million Series BPR Newswire•Jan 12, 2026•Forge Life Science Partners, Kinaset Therapeutics, EQT, RA Capital Management and 8 others
•
•
BlossomHill Therapeutics Secures $84M for Macrocyclic EGFR ApproachEndpoints•Dec 10, 2025•BlossomHill Therapeutics, BioTrack Capital, Cormorant Asset Management, Vivo Capital and 4 others
•
